P005091Ubiquitin-specific protease 7 (USP7) inhibitor CAS# 882257-11-6 |
- USP7-USP47 inhibitor
Catalog No.:BCC4113
CAS No.:1247825-37-1
- NSC 632839 hydrochloride
Catalog No.:BCC2088
CAS No.:157654-67-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 882257-11-6 | SDF | Download SDF |
| PubChem ID | 2819993 | Appearance | Powder |
| Formula | C12H7Cl2NO3S2 | M.Wt | 348.22 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | P5091 | ||
| Solubility | DMSO : 50 mg/mL (143.59 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone | ||
| SMILES | CC(=O)C1=CC(=C(S1)SC2=C(C(=CC=C2)Cl)Cl)[N+](=O)[O-] | ||
| Standard InChIKey | LKZLGMAAKNEGCH-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H7Cl2NO3S2/c1-6(16)10-5-8(15(17)18)12(20-10)19-9-4-2-3-7(13)11(9)14/h2-5H,1H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective inhibitor of ubiquitin-specific protease (USP) 7 (IC50 = 4.2 μM). Displays little-to-no inhibition of other USP variants or proteases such as caspase, cathepsins and serine proteases; exhibits some activity at USP47. Induces elevated p53 and apoptosis in cancer cell lines; displays antiangiogenic activity in vivo. |
P005091 Dilution Calculator
P005091 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8717 mL | 14.3587 mL | 28.7175 mL | 57.435 mL | 71.7937 mL |
| 5 mM | 0.5743 mL | 2.8717 mL | 5.7435 mL | 11.487 mL | 14.3587 mL |
| 10 mM | 0.2872 mL | 1.4359 mL | 2.8717 mL | 5.7435 mL | 7.1794 mL |
| 50 mM | 0.0574 mL | 0.2872 mL | 0.5743 mL | 1.1487 mL | 1.4359 mL |
| 100 mM | 0.0287 mL | 0.1436 mL | 0.2872 mL | 0.5743 mL | 0.7179 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
P005091 is a selective, potent inhibitor of USP7 deubiquitylating activity, which is demonstrated to downregulate claspin and phosphorylation of the DNA checkpoint kinase Chk1, and to synergize with genotoxic agents. USP7, known as herpes-associated-ubiquitin-specificprotease (HAUSP), is a deubiquitylating enzyme that regulates the levels of the oncoprotein HDM2 and its substrate, the tumor suppressor p53. P005091 accelerated the degradation of HDM2, while analogs of the compound induced dose- and time-dependent increases in the protein levels of p53 and p21.What’s more,P005091 induced apoptosis in numerous cancer cell lines, including both p53+/+ and p53-mutant cancer cell lines.
Reference
Jeffrey G Marblestone. Ubiquitin Drug Discovery & Diagnostics 2009 – First Annual Conference. IDrugs. 2009; 12(12):750 – 753.
- H-Ile-OAll.TosOH
Catalog No.:BCC2963
CAS No.:88224-05-9
- H-Leu-OAll.TosOH
Catalog No.:BCC2969
CAS No.:88224-03-7
- Notopterol
Catalog No.:BCN5386
CAS No.:88206-46-6
- (-)-Chelidonine
Catalog No.:BCN7456
CAS No.:88200-01-5
- Clofibric Acid
Catalog No.:BCC4652
CAS No.:882-09-7
- iMDK
Catalog No.:BCC6365
CAS No.:881970-80-5
- MDL 28170
Catalog No.:BCC2352
CAS No.:88191-84-8
- 3,5,9-Trihydroxyergosta-7,22-dien-6-one
Catalog No.:BCN1318
CAS No.:88191-14-4
- Levistilide A
Catalog No.:BCN1197
CAS No.:88182-33-6
- 26RFa
Catalog No.:BCC6163
CAS No.:881640-56-8
- G-1
Catalog No.:BCC6045
CAS No.:881639-98-1
- Amlodipine
Catalog No.:BCC4396
CAS No.:88150-42-9
- AI-3
Catalog No.:BCC8018
CAS No.:882288-28-0
- R1530
Catalog No.:BCC1879
CAS No.:882531-87-5
- Netobimin
Catalog No.:BCC9100
CAS No.:88255-01-0
- AMG-47A
Catalog No.:BCC6394
CAS No.:882663-88-9
- Polygalasaponin F
Catalog No.:BCN2317
CAS No.:882664-74-6
- HC 067047
Catalog No.:BCC7861
CAS No.:883031-03-6
- CCG 50014
Catalog No.:BCC4897
CAS No.:883050-24-6
- BI 78D3
Catalog No.:BCC8089
CAS No.:883065-90-5
- E 64d
Catalog No.:BCC1127
CAS No.:88321-09-9
- N-Benzyllinolenamide
Catalog No.:BCN6531
CAS No.:883715-18-2
- N-Benzyloleamide
Catalog No.:BCN1317
CAS No.:101762-87-2
- (9Z,12Z)-N-(3-Methoxybenzyl)octadeca-9,12-dienamide
Catalog No.:BCN1316
CAS No.:883715-22-8
The multifaceted roles of USP7: new therapeutic opportunities.[Pubmed:21468693]
Cell Biochem Biophys. 2011 Jun;60(1-2):61-8.
The deubiquitylating enzyme USP7 (HAUSP) sits at a critical node regulating the activities of numerous proteins broadly characterized as tumor suppressors, DNA repair proteins, immune responders, viral proteins, and epigenetic modulators. Aberrant USP7 activity may promote oncogenesis and viral disease making it a compelling target for therapeutic intervention. Disclosed drug discovery programs have identified inhibitors of USP7 such as P005091 with cellular proof of concept and anti-proliferative activity in cancer models. Taken together, USP7 inhibitors hold promise as a new strategy for the treatment of disease.
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.[Pubmed:22975377]
Cancer Cell. 2012 Sep 11;22(3):345-58.
Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility. Here, we show that P5091 is an inhibitor of deubiquitylating enzyme USP7, which induces apoptosis in MM cells resistant to conventional and bortezomib therapies. Biochemical and genetic studies show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity. In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival. Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity. Our preclinical study therefore supports clinical evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.
